MYC inhibition associated mechanism research of Group3 medulloblastoma
10.3760/cma.j.issn.1673-422X.2019.10.009
- VernacularTitle: Group3型髓母细胞瘤MYC抑制相关机制的研究
- Author:
Xilin YANG
1
;
Xiaopin CHEN
1
Author Information
1. Department of Oncology, First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China
- Publication Type:Review
- Keywords:
Medulloblastoma;
Genes, MYC;
Group3;
Treatment mechanism
- From:
Journal of International Oncology
2019;46(10):613-616
- CountryChina
- Language:Chinese
-
Abstract:
Medulloblastoma (MB) is the most prevalent pediatric brain tumor. Group3 MB is the most malignant subgroup, quiet a part of which are MYC-amplified. Blocking the upstream gene sites of MYC is mainly achieved through the blockade of miR-494, DDX3, NOTCH1 pathway; BETi or ATR/Chk1 double-inhibition realizes the inhibition of duplication or transcription of MYC; as to the blockade of downstream genes of MYC, researchers mainly focus on LDHA, SETD8 and EZH2. All of these researches which target on MYC-amplified associated anti-tumor treatment mechanism present the theoretical basis for anti-MYC-associated medulloblastoma clinically.
